Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
- The agreement calls for a minimum of 500,000 bottles in sales over 18 months
- T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company's 3CL Protease Inhibiting Antiviral Drug Candidate